Children with newly diagnosed immune thrombocytopenia (ITP) treated with eltrombopag as a frontline therapy show significantly improved platelet responses and other outcomes compared with the standard ...

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal ...

An expert discusses how rilzabrutinib uniquely improves quality-of-life metrics, including fatigue and women’s health domains, which previous immune thrombocytopenia (ITP) therapies failed to address ...

An expert discusses the importance of patient education and personalized, flexible treatment planning in managing chronic immune thrombocytopenic purpura (ITP), highlighting proactive strategies like ...

SAN DIEGO -- Treatment with an investigational oral inhibitor of Bruton's tyrosine kinase (BTK) was safe and boosted platelet counts in heavily pretreated patients with immune thrombocytopenia (ITP), ...

The FDA expanded the approval of Cablivi to include pediatric patients 12 years and older with acquired thrombotic thrombocytopenic purpura.

Immune thrombocytopenia (ITP) is a rare blood disorder in which the immune system mistakenly attacks and destroys platelets. Platelets are small blood cells that play a critical role in helping your ...

Please provide your email address to receive an email when new articles are posted on . Adding ianalumab to second-line eltrombopag prolonged time to treatment failure by more than 40%. Researchers ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window NEW ORLEANS -- ...

Medically reviewed by Gagandeep Brar, MD Key Takeaways ITP does not increase the risk of getting or having severe ...

The 2025 American Society of Hematology (ASH) meeting in December presented a clear message: scientific innovation and ...